SCH 497079Alternative Names: SCH-497079
Latest Information Update: 27 May 2010
At a glance
- Originator Merck & Co
- Class Obesity therapies
- Mechanism of Action Histamine H3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity